Revisiting a null hypothesis: exploring the parameters of oligometastasis treatment

Jessica A. Scarborough^{1,2}, Martin C. Tom³, Michael W. Kattan⁴, and Jacob G. Scott^{1,2,5}✉

¹Translational Hematology and Oncology Research, Cleveland Clinic

²Systems Biology and Bioinformatics Program, Department of Nutrition, Case Western Reserve School of Medicine

³Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, Florida

⁴Department of Quantitative Health Sciences, Cleveland Clinic

⁵Radiation Oncology, Cleveland Clinic

In the treatment of patients with metastatic cancer, the current paradigm states that metastasis-directed therapy does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis: patients garner no overall survival benefit from targeting metastatic lesions. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated. As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear. In this work, we suggest shifting this qualitative null hypothesis, and describe a mathematical model which can be used to frame a new, quantitative null. We begin with a very simple formulation of tumor growth, an exponential function, and illustrate how the same intervention (removing a given number of cells from the tumor) at different times effects survival. Additionally, we postulate where recent clinical trials fit into this parameter space and discuss the implications of clinical trial design in changing these quantitative parameters. Our model shows that while any amount of cell kill will extend survival, in many cases the extent is so small as to be unnoticeable in a clinical context or out-weighted by factors related to toxicity and treatment time. Recasting the null in these quantitative terms will allow trialists to design trials specifically to increase understanding of what circumstances (patient selection, disease burden, tumor growth kinetics) can lead to improved OS when targeting metastatic lesions, rather than whether or not targeting metastases extends survival for patients with (oligo-)metastatic disease.

oligometastasis | mathematical oncology | radiation therapy | cancer

Correspondence: scottj10@ccl.org

1 Introduction

In the treatment of patients with metastatic cancer, the current paradigm states that targeted treatment of metastatic lesions does not prolong life. This paradigm forms the basis of clinical trial null hypotheses, where trials are built to test the null hypothesis: patients garner no overall survival (OS) benefit from targeting metastatic lesions.

The development of distant metastases is the forerunner of cancer-related death (1–3). A Hallmark of Cancer, the dissemination of cancer cells from their origin to distant sites results from a complex cascade of biological events, which may subsequently allow for even more efficient tumor propagation (4–6). Eradicating the body of as much metastatic disease as feasibly possible to halt said process is a natural incli-

nation. Yet, historically, a guiding principle in treating cancer has been that targeting metastatic lesions leads to poor outcomes, because the treatment is either too late or too morbid. However, with advancing imaging technology and increasingly precise techniques for targeting lesions, a much larger proportion of metastatic disease can be treated (7). As a result, the life-extending benefit of targeting metastatic disease is becoming increasingly clear.

Metastatic stage is typically described as a binary variable in a clinical setting, either present or not (M0 or M1), although certain cancer subtypes (e.g. colon, prostate) now have more gradation in classifying a patient's metastatic stage (8). The term “oligometastatic state” was first described in 1995 as an intermediary between localized and widespread metastatic disease where metastasis-directed treatment has the potential to be curative (9). Since then, results from several exploratory studies and randomized controlled trials using metastasis-directed therapy in such patients have accumulated to support its existence (10, 11).

Consensus definitions have since been proposed to further refine subgroups of oligometastasis (12–14). For example, the distinction between oligometastatic disease at presentation versus the development of oligometastatic disease following definitive treatment of non-metastatic cancer have been designated “synchronous oligometastases” and “metachronous oligorecurrence,” respectively. “Oligoprogression” describes growth of few metastases in the setting of otherwise stable (or responsive) disease whilst undergoing systemic therapy, and “oligopersistence” is characterized by having several lesions which have a poorer response to systemic therapy than others. Intra-patient heterogeneity often complicates diagnostics even further, where some lesions respond to therapeutics while others persist. These designations (and many more not listed) underscore the complexity with which researchers and clinicians are coming to understand this disease state.

In addition to refining the term “oligometastatic,” clinicians have examined the benefit of treating patients with oligometastases (28, 29). The implicit null hypothesis of these investigations, that targeting metastatic disease does not provide a life-extending benefit, stems from the current paradigm of metastatic cancer treatment. Table 1 summarizes the results of some of these recent phase II and III clinical trials, demonstrating that this null hypothesis is fre-

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Citation	CT Phase	Primary Location	Results	Description
(15, 16)	II	NSCLC	Positive for PFS and OS	In the Gomez et al. trial, treating oligometastases (≤ 3 non-primary lesions) demonstrated significant improvement in PFS and OS compared to maintenance therapy alone.
(17)	II	NSCLC (EGFR/ALK negative)	Positive for PFS	In the trial by Iyengar et al., targeting the primary with radiotherapy and oligometastases with SBRT followed by maintenance chemotherapy provided significantly improved progression-free survival compared to maintenance chemotherapy alone.
(18, 19)	II	Variety	Positive for OS	In the “SABR-COMET” trial, treating all sites of oligometastatic cancer with SABR demonstrated significantly improved OS compared to standard palliative treatment.
(20)	II	Prostate (hormone sensitive)	Positive for composite of progression metrics	In the “ORIOLE” trial, treating all sites of oligometastases with SABR led to improved outcomes measured by 6-month rate of progression (by PSA, imaging, symptoms, androgen-deprivation therapy initiation, and survival) when comparing to observation alone.
(21)	II	Prostate	Positive for ADT-free survival	In the “STOMP” trial, in patients with metachronous oligometastasis, using metastasis-directed therapy (SBRT or surgery) provided longer ADT-free survival compared to surveillance alone.
(22, 23)	II	CRC	Positive for OS	In the “EORTC 40004” trial, treating liver metastases (<10 , no extrahepatic disease) with RFA, systemic treatment, and +/- resection led to long-term OS improvement compared to systemic treatment alone.
(24)	II	ES-SCLC	Positive for PFS, negative for OS	In the “RTOG 0937” trial, treating oligometastases with PCI and consolidative radiotherapy to both the chest and metastases did not improve OS and did delay progression, compared to PCI alone.
(25)	III	Prostate	Positive for PSA progression, negative for OS	In the “HORRAD” trial, in patients with metastases to the bone (any amount), providing radiotherapy to the prostate along with ADT did not improve OS and did improve time to PSA progression, compared to ADT alone. Exploratory subgroup analysis suggested patients with ≤ 4 bone metastases may benefit from prostate radiotherapy.
(26)	III	Prostate	Negative for OS in complete group, positive for OS in patients with lower metastatic burden	In Arm H of the “STAMPEDE” trial, radiotherapy to the prostate did not improve OS in unfiltered cohort of patients, compared to lifelong ADT. However, in a pre-specified subgroup analysis, significant OS improvement was observed among those with lower metastatic burden.
(27)	III	Nasopharynx	Positive for PFS and OS	In a trial by You et al., the addition of locoregional radiotherapy to the primary improved OS and PFS compared to chemotherapy alone in patients with (oligo- and poly-) metastatic nasopharyngeal carcinoma.

Table 1. A summary of clinical trials that examine the benefit of providing local treatment to patients with oligometastases.

quently (but not always) refuted. Even accounting for known positive publication bias (30, 31), there is substantial evidence that supports a changing paradigm in the treatment of oligometastatic patients. However, despite many studies showing a significant increase in overall survival (OS) when metastatic lesions are targeted, the null hypothesis in ongoing

clinical trial planning has not changed.

In this work, we suggest shifting this qualitative null hypothesis, and describe a mathematical model which can be used to frame a new, quantitative null. We begin with a very simple formulation of tumor growth, an exponential function, and use it to show that while any amount of cell kill

will extend survival, in many cases the extent is so small as to be unnoticeable in a clinical context or out-weighted by factors related to toxicity and treatment time. Recasting the null in these quantitative terms will allow trialists to design trials specifically to increase understanding of what circumstances (patient selection, disease burden, tumor growth kinetics) can lead to improved OS when targeting metastatic lesions, rather than determining whether targeting metastases can extend survival for patients with (oligo-)metastatic disease. We purposely begin with the most simplistic possible mathematical model, considering only total disease burden and doubling time. We do not consider complexities such as space, metastatic locations/connectedness (32), immune interactions or any heterogeneities – all things which could be considered in future iterations, but which make the model less generalizable. Finally, a sensitivity analysis is performed to confirm that our findings are consistent using alternative ordinary differential equations (ODEs) that may be used to model tumor growth (33).

Due to its breadth, the current qualitative null hypothesis may be incorrectly accepted or rejected without a quantitative model to help design optimal patient and treatment parameters. Numerous qualitative and quantitative prognostic factors exist to help identify patients with metastatic disease which is likely to follow a relatively indolent course. For example, with slower disease progression, patients are more likely to derive greater benefit from aggressively targeting their metastases. Other characteristics include the number of lesions and organs involved, the time course of presentation and progression, tumor histology, patient innate and adaptive immunity, and various biological features (34). It is crucial that we parse through which of these patient characteristics can meaningfully affect treatment outcomes in the setting of oligometastasis. By rethinking the null hypothesis of metastatic cancer treatment, research efforts can better serve our patients by bringing a deeper understanding of how well treatment works, who it works best for, and when it is most efficacious, rather than continually testing the implicit null hypothesis.

Model

Modeling Tumor Growth using an Exponential Function. Beginning with a very simple model of tumor growth, an exponential function, we will explore the effect of treatment in scenarios with different growth rates, treatment effectiveness, and timing of the intervention. While this overlooks many of the realities of real human cancers, such as spatial, intra- and inter-tumoral (35–37) heterogeneity, it captures many of the essential aspects of growth (38). Furthermore, in the absence of other specific knowledge, general arguments can be expounded upon, but additional undetermined complexities can severely limit generalizability. Let us then model a tumor of size (cell number), N , beginning with a single cell, and a growth rate, r , as follows:

$$N(t) = e^{rt}. \quad (1)$$

A growth curve built using Equation 1 is displayed in Figure 1 as the black line, denoted “Untreated.” The threshold tumor burden (an arbitrary number of $N = 100$ for illustrative purposes) which leads to patient death, N_T , is represented by the horizontal black dashed line in Figure 1. Next, we will assume that a given intervention (e.g. stereotactic body radiation therapy (SBRT), or metastasectomy) is given at some time (e.g. upon detection of a metastasis). The total tumor burden at the time of this treatment is denoted as N_d and the number of cells killed is denoted as N_c cells; note, this requires $0 \leq N_c \leq N_d$.

To illustrate how the same intervention (removing N_c cells from the tumor) at different times effects our measure of survival, we plot several growth curves together in Figure 1. The time when each of these curves reaches N_T is the time of death ($t_{d,x}$). The difference (Δt) between the unperturbed time of death ($t_{d,1}$) and each subsequent example intervention (e.g. $\Delta t = t_{d,2} - t_{d,1}$) is the increase in survival. We note that the earlier the intervention occurs (smaller N_d), the greater the Δt and, therefore, increase in survival. This is also true if we kill more cells (i.e. N_c increases).

While Figure 1 considers how a single intervention will effect the “same” tumor, Supplementary Figure 1 explores the effect of altering tumor growth rate, r , on Δt after the same intervention. This figure adds a faster tumor growth curve, in addition to the curve seen in Figure 1. The same intervention (removal of N_c cells) occurs at the same time points as the slower curve, yet the faster growing tumor has a smaller resulting changes in survival time (Δt_f) compared to the slower growing tumor (Δt_s).

Next, we will examine the analytical relationship between the change in survival (Δt) to the other parameters (r , N_c , N_d). This requires examining two tumor growth curves, one with unperturbed growth starting at N_d and the other with perturbed growth beginning at $(N_d - N_c)$. In other words, the perturbed curve will have the same growth characteristics as the unperturbed curve, but it will have N_c cells removed as “treatment.” Then, we will calculate the offset of time between the two curves when they reach N_T , i.e. Δt .

Graphically, we are asking how large the difference on the time axis is between where the treated and untreated curves intersect with N_T (the black dashed line), denoted by colored circles in Figure 1 and Supplementary Figure 1. Mathematically, we find the difference between $t_{d,1}$ and $t_{d,2}$: i.e. Δt when $(N_d)e^{rt_1} = (N_d - N_c)e^{rt_2} = N_T$. This relation is:

$$\Delta t = \frac{1}{r} \left[\ln \frac{N_d}{(N_d - N_c)} \right]. \quad (2)$$

The observations from before are maintained: slower growing tumors (smaller r), more effective interventions (increasing N_c), and lower burden at time of treatment (lower N_d) make for a larger survival benefit, as we have intuited. Additionally, it is important to note that Δt is not dependent on the threshold chosen for N_T , where tumor burden leads to death.

Given the intuitive nature of these results, one may question what the value of such a model is. First, this model al-

Fig. 1. Change in OS is modulated by when an oligometastasis-directed intervention occurs and the effectiveness of the intervention. We plot an illustrative exponential growth curve from Equation 1 in black. At three different times, we subtract N_c cells from the curve to simulate an oligometastasis-directed intervention (orange markers), and the tumor continues to grow at the original rate from the new size. These subsequent tumors then grow and eventually intersect an arbitrary threshold cell (a surrogate for maximum tolerated disease burden) number (N_T - dashed horizontal line), there we can then determine the change in survival (vertical black lines, inset). The change in this time represents the Δt for each intervention. n.b. These are not realistic parameters, but instead serve to illustrate the (qualitatively conserved) phenomenon.

lows for the quantitative exploration of what was previously an exclusively qualitatively described phenomenon. This allows for formal interrogation of the individual values of each parameter, a crucial step in quantitative reasoning during clinical trial design. In doing so, a framework for parameter estimation can help trialists perform sensible power calculations. This would require measuring distributions of each of these parameters as it is clear that heterogeneity (and uncertainty) exists in each. Further, this would allow for error propagation in addition to power calculations. With recent work trying to incorporate toxicity into survival analyses in radiation oncology (39), we have the opportunity to formally probe the balance between benefit and harm in this setting. Most importantly however, it will remove the confusion created when we test a qualitative null that is likely neither able to be rejected or upheld given the sensitivity to the noise inherent in clinical data.

Sensitivity Analysis with Alternative Tumor Growth Models. In order to assess the consistency of our findings, we examined the seven ODE models used in Murphy et al., 2016 (33), where they fit each model using 14 time points from a naked mouse xenograft experiment by Worschech et al., 2009 (40). The models included in this analysis are as follows: exponential, Figure 2A shows all seven models

(including the exponential model) built using the parameters denoted by Murphy et al (33). Using these models, Figure 2B denotes the Δt , or change in OS, between the untreated growth curves and growth curves with the same intervention at early, middle, and late timing. Here, we see that all models show that the same intervention has a greater benefit the earlier it is performed. Each model with untreated, early, middle, and late interventions is individually plotted in Supplementary Figure 2B-H, while Supplementary Figure 2A shows all untreated models together for comparison. Although not all models have as extreme of a difference as seen in the exponential model, this quantitative trend, which is the main thrust of this study, remains consistent.

Parameter Sweep of Exponential Growth Model. Figure 3 demonstrates a benefit of using a quantitative model with a sensitivity analysis to help us better understand the areas of the (very simplified) parameter space, a range of possible parameter values, where the greatest opportunities lie. Given that this is a simple exponential relation, the change in survival is monotone (always up or down) in each parameter. However, as the tumor growth curves are non-linear, we chose to plot the sensitivity analysis on a log-log plane to improve the visualization of changes in parameter values.

As we do not currently have known values for these pa-

Fig. 2. Across seven ODE tumor growth models, earlier intervention creates a larger improvement in OS. Models were produced using the parameters denoted by Murphy et al (33), where the seven models were fit to 14 timepoints of xenograft tumor growth data from Worschech et al (40). **A.** A comparison of the seven growth curves with no interventions built with various ODE models. Individual plots for each model and three intervention time points may be found in Supplementary Figure 2. **B.** A heatmap demonstrating the change in OS (Δt days) for the same intervention ($N_C = 100$) at three different time points for each ODE model. Each heatmap entry is annotated with the exact change in OS for the given model and intervention timing. Treat early, treat middle, and treat late denote the intervention occurring at 20, 35, and 50 days, respectively.

rameters, exploring a large sweep of values can be instructive. We consider a continuous range for N_c in $[0, N_d]$, where $N_c = 0$ represents no intervention and $N_c = N_d$ represents a cure. In these cases, $\Delta t = 0$ and $\Delta t = \infty$, respectively. In Figure 3, we will consider four discrete examples of values for r , as this parameter's effect is monotone (where a case with lower r always derives more benefit from oligometastasis-directed therapy than a case with higher r). It is also important to note that this parameter is likely modifiable with chemo- or targeted-therapy: something we do not consider here, but would be a straightforward extension. This example will consider growth rates which correspond to tumor doubling times of 100, 200, 300 and 400 days. These could represent tumors such as small cell lung cancer in the fast extreme or prostate cancer in the slow extreme. Figure 3 shows this analysis, with isoclines shown in black to denote lines of equal effect. These curves demonstrate that any increase in N_c (more cell kill per intervention, "up" on the y-axis) and/or decrease in N_d (earlier intervention, "down" on the x-axis) increases the OS benefit. It is interesting to note that the movements (i.e. N_c up and N_d down) mirror the historical trend: improvements in detection of oligometastasis via anatomic or functional imaging have slowly pushed N_d lower over the years and the ability to safely (using SBRT

or minimally invasive surgery with continually lowering toxicity) target larger and larger lesions (increasing N_c) has increased. This "creep" of these values is one reason why the need for a recasting of the null hypothesis is becoming clear, and why the null was historically of greater clinical utility.

Sample Size Calculation Informed by Exponential Growth Model. Finally, we performed theoretical sample size calculations (using the Sample Size Estimator from Wang et al., 2020 (41)) in four clinical scenarios: a fast growing tumor type which is detected early, a fast growing tumor type which is detected late, a slow growing tumor type which is detected early, and a slow growing tumor type which is growing late. Using Equation 2, we assume parameters which are congruent with each clinical scenario and calculate the change in survival time between the treated and untreated growth curves. These Δt 's are then converted into hazard ratios (HR) relative to each other, with the largest change in survival time relating to the most extreme HR (0.50) and the smallest change in survival time leading to the HR closest to 1 (0.80). In Table 2, we see that as the HR approaches 1, the predicted sample size requirements become unreasonable for any oncology treatment clinical trial. This HR may occur in a trial with a fast growing tumor type (e.g. SCLC) that has

Fig. 3. The benefit of oligometastasis-directed therapy depends monotonically on the amount of cells killed, the tumor burden, and tumor doubling time. We plot four orders of magnitude of both N_c and N_d on a log scale. The color represents the predicted number of days of OS (PFS in the ORIOLE trial) benefit for each combination of N_c and N_d . Each of the four subplots represents a different “intrinsic” biology, modeled by different tumor doubling times. A t_d of 100, 200, 300, and 400 days corresponds to a growth rate, r , of 0.0069, 0.0035, 0.0023, and 0.0017, respectively. Contour lines are shown for ease of comparison. A selection of trials from Table 1 are represented by red circles based on estimations of N_d , N_c , r , and t_d for each trial.

Tumor Parameters	Doubling Time (days)	Growth Rate (r)	N_d	N_c	Δt (days)	HR	Sample Size
Fast growing tumor, early detection	100	0.0069	$10E10$	$5E10$	100.0	0.60	82
Fast growing tumor, late detection	100	0.0069	$10E11$	$5E10$	7.4	0.80	14698
Slow growing tumor, early detection	400	0.0017	$10E10$	$5E10$	400.0	0.50	34
Slow growing tumor, late detection	400	0.0017	$10E11$	$5E10$	29.6	0.70	322

Table 2. Theoretical sample size calculations demonstrate that as the change in OS decreases, the hazard ratio (HR) gets closer to 1, and a larger sample size is predicted. Using Equation 2, Δt , representing change in OS, was calculated for four clinical scenarios. This predicted change in OS is translated to an estimated hazard ratio to perform a sample size calculation. The sample size calculations assumed a type I error (α) of 0.05, power ($1 - \beta$) of 0.80, equal size of treatment arms, and a superiority margin of 0.20. Sample size was estimated using a resource by Wang et al., 2020 (41) (<http://riskcalc.org:3838/samplesize/>), which references Schoenfeld et al., 1981 (42) and 1983 (43) for the calculation of sample size in parallel randomized control trials for assessing superiority of a treatment using time-to-event.

widespread metastatic disease.

As seen in McClatchy III et al., 2020 (44) and XXXX et al., 2020 (39), a more technical method of assessing these theoretical sample size calculations would be to perform an *in silico* clinical trial. One would assume distributions for each parameter of interest (e.g. r , N_d), sample each “patient” in the trial from these distributions, assess survival time for treated and untreated groups, and calculate the HR between the two groups. Even with this theoretical approach, however, additional measurements would be required to appropriately estimate the distributions of the model parameters. Post-trial data publication could provide a wealth of information to estimate these parameters. For example, tumor imaging both before and after treatment could assess N_d and N_c , while serial tumor biopsies could be used to inform a distribution for tumor growth rate. Without these data, however, we believe that the simpler method of converting Δt to HR shown in Table 2, provides an easier-to-interpret example of sample size calculations.

Clinical correlation

In order to demonstrate how clinical trial design can explore the parameter space of this tumor growth model, we will review some recent clinical trials, which are also listed in Table 1. This discussion reviews illustrative examples, and is not an exhaustive list of all clinical trials which test the benefit of targeting oligometastases. For many trials, we will estimate where design falls in the parameter space of Figure 3, and discuss how trial design can test the effects of altering one or more parameters (i.e. N_d , N_c , or r).

In a phase II trial by Gomez et al., 49 patients with oligometastatic (≤ 3 metastases) non-small cell lung cancer (NSCLC) without progression after first-line systemic therapy were randomized to either maintenance systemic therapy/surveillance or local consolidative therapy (LCT) to all sites of residual disease via surgery or radiotherapy. After interim analysis demonstrated a substantial PFS benefit with LCT, the trial was closed early and allowed for crossover to the LCT arm (15). With additional follow up, and despite crossover, LCT was associated with improved OS of 41.2 months vs 17.0 months (16). We placed this trial in the top right subplot of Figure 3, due to the relatively fast growth rate of NSCLC, minimal tumor burden (≤ 3 metastases), and large N_c using radiotherapy or surgery.

The SABR-COMET study was a screening phase II trial which randomized 99 patients with oligometastatic disease (≤ 5 metastases) of various histologies with a controlled primary site to standard palliative therapy with or without stereotactic ablative radiotherapy (SABR) to all metastatic lesions. The primary endpoint was OS, which was initially improved with the addition of SABR from 28 months to 48 months (19). With additional follow up, results were even more substantial with a median OS of 50 months using SABR versus 28 months in the control arm (45). As this trial includes tumors of many histologies, we cannot place the positive results in a single subplot of Figure 3, but doing so *post-hoc* patient by patient would be illustrative. The SABR-

COMET trial also utilized stratified randomization to ensure that strata of patients with 1-3 metastases and 4-5 metastases were balanced in treatment assignments. Stratified randomization helps balance treatment arm assignments between patient populations with known prognostic factors, and can reduce the risk of type I and II errors in trials with smaller sample sizes (<400 patients) (46). In relation to our model, by creating strata of the number of metastases, the SABR-COMET trial balanced based on tumor burden at the time of treatment (N_d). In future, other trials may consider stratifying based on tumor growth rate (either inferred by tumor type or measured from serial tumor biopsies), the sensitivity of imaging techniques (N_d or N_c), or the efficacy of two treatment types (N_c).

In the phase II EORTC 40004 trial, 119 patients with fewer than 10 unresectable colorectal liver metastases and no extrahepatic disease were randomized to systemic therapy with or without local therapy using RFA (with or without resection). Although the primary endpoint of 30 month OS was not met, longer follow up led to improved OS with RFA from 40.5 months to 45.6 months (23). With a relatively slow growing tumor sub-type, a large N_d , and a moderate OS benefit, we estimated this clinical trial to fall in the bottom left subplot of the model’s parameter space found in Figure 3.

The largest study was Arm H of the STAMPEDE trial, which was a phase III trial of 2061 patients with metastatic prostate cancer randomized to androgen deprivation therapy with or without definitive radiotherapy to the prostate. Pre-specified subgroup analysis demonstrated no benefit to the addition of prostate radiotherapy among those with a high metastatic burden, defined as either visceral metastases or ≥ 4 bone metastases with ≥ 1 outside of the vertebral bodies or pelvis. However, in the group of 819 patients with a low metastatic burden, radiotherapy to the prostate improved three-year OS from 73 percent to 81 %. (26) In relation to our model, this is equivalent to assuming that the two groups (high and low metastatic burden) have different N_d at the time of treatment, but experience the same N_c . It should be noted that unlike other trials discussed, local therapy was delivered only to the primary site, but not the metastatic sites, suggesting a benefit to cytoreduction. The estimated parameter space position of these two subgroups (high metastatic burden and low metastatic burden) is found in the bottom right subplot of Figure 3.

In the ORIOLE trial, patients with metachronous oligometastatic prostate cancer with ≤ 3 sites as detected by conventional imaging were randomized to surveillance or SABR to all sites (20). The primary endpoint was a composite of disease progression metrics at 6 months, which was improved with SABR at 19% versus 61% in the control arm. Interestingly, a subgroup of patients underwent advanced imaging with PSMA PET, which has demonstrated greater sensitivity in detecting prostate cancer metastases (putatively lowering N_d) (47). Among those patients where all PSMA PET avid sites were treated, the 6 month progression rate was just 5% compared to 38% in those with untreated sites. This subgroup analysis further supports that advanced imaging can

better identify metastases and treating all sites improves outcomes. By utilizing a more sensitive technology in detecting (and therefore targeting) metastases, we see that a greater N_c increases PFS, even if N_d remains the same. We estimate the parameter space for this subgroup analysis in the bottom right subplot of Figure 3.

Not all trials have demonstrated benefit to the addition of metastasis-directed therapy. For example, RTOG 0937 was a phase II study of 86 patients with extensive stage small cell lung cancer with at least a partial response to chemotherapy and 1-4 extracranial metastases who were randomized to prophylactic cranial irradiation with or without consolidative radiotherapy to the chest and all metastatic sites. The primary endpoint of one-year OS was not significantly different; 60% in the control arm and 51% in the consolidative radiotherapy arm (24). This negative result is estimated to be in the top left subplot of Figure 3, due to the rapid growth of SCLC. Here, this model could have still been useful by informing the sample size calculations (Table 2), given the parameter estimates of the trial's patient population.

Conclusions

In this work, we have used a simple exponential model of tumor growth to demonstrate why recent improvements in metastasis detection and treatment may allow us to reconsider the null hypothesis when treating patients with oligometastases. Specifically, more sensitive techniques to localize metastases (as seen with PSMA imaging) increases how many tumor cells are removed, N_c , when considering patients at similar stages. When used for surveillance, these imaging techniques can decrease the tumor burden at the time of treatment, N_d , while still increasing the efficacy of therapy, N_c , potentially leading to clinically significant improved OS. Next, advancements in the ability to administer local therapy to all sites of disease with surgical resection, radiotherapy, and/or ablative procedures such as radiofrequency ablation (RFA) has allowed for more effective, precise eradication of metastatic lesions with reduced associated morbidity. Furthermore, novel immuno- and targeted-therapies can likely decrease the growth rate, r , of tumors.

A mathematical model provides the distinct advantage of testing quantitative hypotheses to optimize the treatment of patients with oligometastases. Parameter selection regarding number of oligometastases, measurements of tumor burden, and efficacy of treatment options can be examined with robust hypotheses born from simulated results. Additionally, with increased translation between the bench and bedside, some model parameters (e.g. r , tumor growth rate) may be inferred using serial tumor biopsies, *in vitro*, or *in silico* modeling. A deeper understanding of how these parameters affect outcome can improve trial design by allowing for rational prognostic strata criteria in stratified randomization or informing prior probabilities in a Bayesian clinical trial (46, 48, 49). Furthermore, Bayesian trial interim analyses can be enhanced with additional simulations using updated parameters as patient characteristics are observed or assessed over time. With a better understanding of the prognostic factors of the population enrolled in a trial, these interim analyses may be used to update prior probabilities, predict probability of success, and assess sample size requirements (48, 49).

It is important to note that the model demonstrated in this work is not a perfect representation of tumor growth and treatment, as it fails to consider intratumoral heterogeneity, metastasis location, and the inherent risks of treatment. However, because of its simplicity, this model provides a foundation exploring the current parameter space, while allowing researchers to add complexity as they see fit.

There are minimal published clinical trial results which support upholding the current paradigm in the treatment of oligometastases; however, this is likely due in part to publication bias where positive results are more likely to be published, not simply because this null hypothesis has always been rejected (30, 31). The clinical trials examined in this manuscript have necessarily sought to examine the fundamental idea that oligometastatic lesions should only be targeted for palliative care. Refuting this standard was crucial, as the earlier state of cancer imaging and treatment established that targeting oligometastases either occurred too late or caused too much harm. Yet, as quantitative models of tumor growth and the knowledge of how metastatic detection and treatment have evolved, we believe that clinical trials can now provide an even greater benefit by reconsidering the default null hypothesis and utilizing the quantitative principles of this mathematical model in trial design.

Code Availability

All code used to create mathematical models and figures in this manuscript may be found on GitHub at <https://github.com/jessicascarborough/oligomet-null-hypothesis>.

ACKNOWLEDGEMENTS

JGS thanks his patients for providing him with motivation to push the boundaries of what we know. He would also like to thank the NIH for their support through NIH R37CA244613 and their generous Loan Repayment Program and the American Cancer Society for the Research Scholar Grant (Award number: 132691-RSG-20-096-01-CSM). JAS was supported in part by NIH grant T32 GM007250.

Bibliography

- Christine L Chaffer and Robert A Weinberg. A perspective on cancer cell metastasis. *Science*, 331(6024):1559–1564, 2011.
- Hanna Dillekås, Michael S Rogers, and Oddbjørn Straume. Are 90% of deaths from cancer caused by metastases? *Cancer medicine*, 8(12):5574–5576, 2019.
- Thomas N Seyfried and Leanne C Huysentruyt. On the origin of cancer metastasis. *Critical reviews in oncogenesis*, 18(1-2):43, 2013.
- Douglas Hanahan and Robert A Weinberg. The hallmarks of cancer. *cell*, 100(1):57–70, 2000.
- Jacob Scott, Peter Kuhn, and Alexander RA Anderson. Unifying metastasis—integrating intravasation, circulation and end-organ colonization. *Nature Reviews Cancer*, 12(7):445–446, 2012.
- Scott Valastyan and Robert A Weinberg. Tumor metastasis: molecular insights and evolving paradigms. *Cell*, 147(2):275–292, 2011.
- Sondos Zayed, Rohann JM Correa, and David A Palma. Radiation in the treatment of oligometastatic and oligoprogressive disease: Rationale, recent data, and research questions. *The Cancer Journal*, 26(2):156–165, 2020.
- Mahul B Amin, Frederick L Greene, Stephen B Edge, Carolyn C Compton, Jeffrey E Gershengwald, Robert K Brookland, Laura Meyer, Donna M Gress, David R Byrd, and David P Winchester. The eighth edition ajcc cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. *CA: a cancer journal for clinicians*, 67(2):93–99, 2017.
- Samuel Hellman and Ralph R Weichselbaum. Oligometastases. *Journal of Clinical Oncology*, 13(1):8–10, 1995.

- 504 10. Sean P Pitroda, Nikolai N Khodarev, Lei Huang, Abhineet Uppal, Sean C Wightman, Sabha 590
505 Ganai, Nora Joseph, Jason Pitt, Miguel Brown, Martin Forde, et al. Integrated molecu- 591
506 lar subtyping defines a curable oligometastatic state in colorectal liver metastasis. *Nature* 592
507 *communications*, 9(1):1–8, 2018. 593
- 508 11. Julian C Hong, Diandra N Ayala-Peacock, Jason Lee, A William Blackstock, Paul Okunieff, 594
509 Max W Sung, Ralph R Weichselbaum, Johnny Kao, James J Urbanic, Michael T Milano, 595
510 et al. Classification for long-term survival in oligometastatic patients treated with ablative 596
511 radiotherapy: a multi-institutional pooled analysis. *PloS one*, 13(4):e0195149, 2018. 597
- 512 12. Ralph R Weichselbaum and Samuel Hellman. Oligometastases revisited. *Nature reviews* 598
513 *Clinical oncology*, 8(6):378, 2011. 599
- 514 13. Matthias Guckenberger, Yolande Lievens, Angelique B Bouma, Laurence Collette, Andre 600
515 Dekker, M deSouza Nandita, Anne-Marie C Dingemans, Beatrice Fournier, Coen Hurk- 601
516 mans, Frédéric E Lecouvet, et al. Characterisation and classification of oligometastatic 602
517 disease: a european society for radiotherapy and oncology and european organisation for 603
518 research and treatment of cancer consensus recommendation. *The Lancet Oncology*, 21 604
519 (1):e18–e28, 2020. 605
- 520 14. Yolande Lievens, Matthias Guckenberger, Daniel Gomez, Morten Hoyer, Puneeth Iyengar, 606
521 Isabelle Kindts, Alejandra Méndez Romero, Daan Nevens, David Palma, Catherine Park, 607
522 et al. Defining oligometastatic disease from a radiation oncology perspective: An estro- 608
523 astro consensus document. *Radiotherapy and Oncology*, 2020. 609
- 524 15. Daniel R Gomez, George R Blumenschein Jr, J Jack Lee, Mike Hernandez, Rong Ye, 610
525 D Ross Camidge, Robert C Doebele, Ferdinandos Skoulidis, Laurie E Gaspar, Don L Gib- 611
526 bons, et al. Local consolidative therapy versus maintenance therapy or observation for 612
527 patients with oligometastatic non-small-cell lung cancer without progression after first-line 613
528 systemic therapy: a multicentre, randomised, controlled, phase 2 study. *The lancet oncol-* 614
529 *ogy*, 17(12):1672–1682, 2016. 615
- 530 16. Daniel R Gomez, Chad Tang, Jianjun Zhang, George R Blumenschein Jr, Mike Hernandez, 616
531 J Jack Lee, Rong Ye, David A Palma, Alexander V Louie, D Ross Camidge, et al. Local con- 617
532 solidative therapy vs. maintenance therapy or observation for patients with oligometastatic 618
533 non-small-cell lung cancer: long-term results of a multi-institutional, phase ii, randomized 619
534 study. *Journal of Clinical Oncology*, 37(18):1558–1565, 2019. 620
- 535 17. Puneeth Iyengar, Zabi Wardak, David E Gerber, Vasu Tumati, Chul Ahn, Randall S Hughes, 621
536 Jonathan E Dowell, Naga Cheedella, Lucien Nedzi, Kenneth D Westover, et al. Consolida- 622
537 tive radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized 623
538 clinical trial. *JAMA oncology*, 4(1):e173501–e173501, 2018. 624
- 539 18. David A Palma, Cornelis JA Haasbeek, George B Rodrigues, Max Dahele, Michael Lock, 625
540 Brian Yaremko, Robert Olson, Mitchell Liu, Jason Panarotto, GwendolynHJM Griffioen, et al. 626
541 Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors 627
542 (sabr-comet): study protocol for a randomized phase ii trial. *BMC cancer*, 12(1):305, 2012. 628
- 543 19. David A Palma, Robert Olson, Stephen Harrow, Stewart Gaede, Alexander V Louie, Cor- 629
544 nelis Haasbeek, Liam Mulroy, Michael Lock, George B Rodrigues, Brian P Yaremko, et al. 630
545 Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients 631
546 with oligometastatic cancers (sabr-comet): a randomised, phase 2, open-label trial. *The* 632
547 *Lancet*, 393(10185):2051–2058, 2019. 633
- 548 20. Ryan Phillips, William Yue Shi, Matthew Deek, Noura Radwan, Su Jin Lim, Emmanuel S 634
549 Antonarakis, Steven P Rowe, Ashley E Ross, Michael A Gorin, Curtland Deville, et al. Out- 635
550 comes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: 636
551 the oriole phase 2 randomized clinical trial. *JAMA oncology*, 6(5):650–659, 2020. 637
- 552 21. Piet Ost, Dries Reynders, Karel Decaestecker, Valérie Fonteyne, Nicolaas Lumen, Aurelie 638
553 DeBruycker, Bieke Lambert, Louke Delrue, Renée Bultjnick, Tom Claeys, et al. Surveillance 639
554 or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospec- 640
555 tive, randomized, multicenter phase ii trial. *Journal of Clinical Oncology*, 2017. 641
- 556 22. T Ruers, C Punt, F Van Coevorden, JPen Pierle, I Borel-Rinkes, JA Ledermann, G Poston, 642
557 W Bechstein, MA Lentz, M Mauer, et al. Radiofrequency ablation combined with systemic 643
558 treatment versus systemic treatment alone in patients with non-resectable colorectal liver 644
559 metastases: a randomized eortc intergroup phase ii study (eortc 40004). *Annals of Oncol-* 645
560 *ogy*, 23(10):2619–2626, 2012. 646
- 561 23. Theo Ruers, Frits Van Coevorden, Cornelis JA Punt, Jean-Pierre EN Pierle, Inne Borel- 647
562 Rinkes, Jonathan A Ledermann, Graeme Poston, Wolf Bechstein, Marie-Ange Lentz, 648
563 Murielle Mauer, et al. Local treatment of unresectable colorectal liver metastases: results of 649
564 a randomized phase ii trial. *JNCI: Journal of the National Cancer Institute*, 109(9):dxj015, 650
565 2017. 651
- 566 24. Elizabeth M Gore, Chen Hu, Alexander Y Sun, Daniel F Grimm, Suresh S Ramalingam, 652
567 Neal E Dunlap, Kristin A Higgins, Maria Werner-Wasik, Aaron M Allen, Puneeth Iyengar, 658
568 et al. Randomized phase ii study comparing prophylactic cranial irradiation alone to pro- 659
569 phylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease 660
570 small cell lung cancer (ed sclc): Nrg oncology rtog 0937. *Journal of Thoracic Oncology*, 12 661
571 (10):1561–1570, 2017. 662
- 572 25. Liselotte MS Boevé, Maarten CCM Hulshof, André N Vis, Aeilko H Zwiderman, Jos WR 663
573 Twisk, Wim PJ Witjes, Karl PJ Delaere, R Jeroen A van Moorselaar, Paul CMS Verhagen, 664
574 and George van Andel. Effect on survival of androgen deprivation therapy alone compared 665
575 to androgen deprivation therapy combined with concurrent radiation therapy to the prostate 666
576 in patients with primary bone metastatic prostate cancer in a prospective randomised clinical 667
577 trial: data from the horrad trial. *European urology*, 75(3):410–418, 2019. 668
- 578 26. Christopher C Parker, Nicholas D James, Christopher D Brawley, Noel W Clarke, Alex P 669
579 Hoyle, Adnan Ali, Alastair WS Ritchie, Gerhard Attard, Simon Chowdhury, William Cross, 670
580 et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer 671
581 (stampede): a randomised controlled phase 3 trial. *The Lancet*, 392(10162):2353–2366, 672
582 2018. 673
- 583 27. Rui You, You-Ping Liu, Pei-Yu Huang, Xiong Zou, Rui Sun, Yu-Xiang He, Yi-Shan Wu, Guo- 674
584 Ping Shen, Hong-Dan Zhang, Chong-Yang Duan, et al. Efficacy and safety of locoregional 675
585 radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyn- 676
586 geal carcinoma: A multicenter phase 3 randomized clinical trial. *JAMA oncology*, 2020. 677
- 587 28. Deepinder Singh, Won Sam Yi, Ralph A Brasacchio, Ann G Muhs, Therese Smudzin, 678
588 Jacqueline P Williams, Edward Messing, and Paul Okunieff. Is there a favorable subset 679
589 of patients with prostate cancer who develop oligometastases? *International Journal of*
- Radiation Oncology* Biology* Physics*, 58(1):3–10, 2004.
29. David A Palma, Joseph K Salama, Simon S Lo, Suresh Senan, Tom Treasure, Ramaswamy 680
Govindan, and Ralph Weichselbaum. The oligometastatic state—separating truth from 681
wishful thinking. *Nature reviews Clinical oncology*, 11(9):549, 2014.
30. Ana Mlinarić, Martina Horvat, and Vesna Šupak Smolčić. Dealing with the positive publica- 682
tion bias: Why you should really publish your negative results. *Biochemia medica: Bio-* 683
chemia medica, 27(3):447–452, 2017.
31. Mohammad Hassan Murad, Haitao Chu, Lifeng Lin, and Zhen Wang. The effect of publica- 684
tion bias magnitude and direction on the certainty in evidence. *BMJ evidence-based* 685
medicine, 23(3):84–86, 2018.
32. Jacob G Scott, David Basanta, Alexander RA Anderson, and Philip Gerlee. A mathematical 686
model of tumour self-seeding reveals secondary metastatic deposits as drivers of primary 687
tumour growth. *Journal of The Royal Society Interface*, 10(82):20130011, 2013.
33. Hope Murphy, Hana Jaafari, and Hana M Dobrovolsky. Differences in predictions of ode 688
models of tumor growth: a cautionary example. *BMC cancer*, 16(1):1–10, 2016.
34. Sean P Pitroda and Ralph R Weichselbaum. Integrated molecular and clinical staging de- 689
fines the spectrum of metastatic cancer. *Nature Reviews Clinical Oncology*, 16(9):581–588, 690
2019.
35. Andriy Marusyk and Kornelia Polyak. Tumor heterogeneity: causes and consequences. 691
Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1805(1):105–117, 2010.
36. Jacob G Scott, Alexander G Fletcher, Alexander RA Anderson, and Philip K Maini. Spatial 692
metrics of tumour vascular organisation predict radiation efficacy in a computational model. 693
PLoS computational biology, 12(1):e1004712, 2016.
37. Jacob G Scott, Anders Berglund, Michael J Schell, Ivaylo Mihaylov, William J Fulp, Binglin 694
Yue, Eric Welsh, Jimmy J Caudell, Kamran Ahmed, Tobin S Strom, et al. A genome-based 695
model for adjusting radiotherapy dose (gard): a retrospective, cohort-based study. *The* 696
Lancet Oncology, 18(2):202–211, 2017.
38. Philip Gerlee. The model muddle: in search of tumor growth laws. *Cancer research*, 73(8): 697
2407–2411, 2013.
39. Jacob G Scott, Geoffrey Sedor, Michael W Kattan, Jeffrey Peacock, G Daniel Grass, Eric A 698
Mellon, Ram Thapa, Michael Schell, Anthony Waller, Sean Poppen, et al. Optimizing clinical 699
outcome and toxicity in lung cancer using a genomic marker of radiosensitivity. *medRxiv*, 700
(JTO, accepted), 2020.
40. Andrea Worschech, Nanhai Chen, A Yu Yong, Qian Zhang, Zoltan Pos, Stephanie Weibel, 701
Viktoria Raab, Marianna Sabatino, Alessandro Monaco, Hui Liu, et al. Systemic treatment 702
of xenografts with vaccinia virus glv-1h68 reveals the immunologic facet of oncolytic therapy. 703
BMC genomics, 10(1):301, 2009.
41. Xiaofeng Wang and Xinge Ji. Sample size estimation in clinical research: from randomized 704
controlled trials to observational studies. *Chest*, 158(1):S12–S20, 2020.
42. David Schoenfeld. The asymptotic properties of nonparametric tests for comparing survival 705
distributions. *Biometrika*, 68(1):316–319, 1981.
43. David A Schoenfeld. Sample-size formula for the proportional-hazards regression model. 706
Biometrics, pages 499–503, 1983.
44. David M McClatchy, Henning Willers, Aaron N Hata, Zofia Piotrowska, Lecia V Sequist, Har- 707
ald Paganetti, and Clemens Grassberger. Modeling resistance and recurrence patterns of 708
combined targeted-chemoradiotherapy predicts benefit of shorter induction period. *Cancer* 709
Research, 80(22):5121–5133, 2020.
45. David Palma, Robert Olson, Stephen Harrow, Stewart Gaede, Alexander V Louie, Cornelis 710
Haasbeek, Liam Mulroy, Michael Lock, George Rodrigues, Brian Yaremko, et al. Stereotac- 711
tic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long- 712
term results of the sabr-comet phase ii randomized trial. *medRxiv*, 2020.
46. Walter N Kernan, Catherine M Viscoli, Robert W Makuch, Lawrence M Brass, and Ralph I 713
Horwitz. Stratified randomization for clinical trials. *Journal of clinical epidemiology*, 52(1): 714
19–26, 1999.
47. Finn E von Eyben, Maria Picchio, Rie von Eyben, Handoo Rhee, and Glenn Baum- 715
an. 68ga-labeled prostate-specific membrane antigen ligand positron emission tomog- 716
raphy/computed tomography for prostate cancer: a systematic review and meta-analysis. 717
European urology focus, 4(5):686–693, 2018.
48. Matthew A Psioda and Joseph G Ibrahim. Bayesian clinical trial design using historical data 718
that inform the treatment effect. *Biostatistics*, 20(3):400–415, 2019.
49. Donald A Berry. Bayesian clinical trials. *Nature reviews Drug discovery*, 5(1):27–36, 2006.

Supplementary Information

Supplementary Fig 1. Change in OS is modulated by tumor growth rate, intervention timing, and intervention efficacy. Top: We plot two illustrative exponential growth curves from Equation 1 in black, using a faster (dotted line) and slower (solid line) growth rate, r . The slower growth rate is the same curves shown in Figure 1. At three different time points, we subtract N_c cells from the two curves to simulate an oligometastasis-directed intervention, and the tumor continues to grow at the original rate from the new size. These subsequent tumors then grow and eventually intersect an arbitrary threshold cell (a surrogate for maximum tolerated disease burden) number (N_T - dashed horizontal line). **Bottom:** We plot two expanded windows of the above plot, showing greater detail of the faster (left, dotted) and slower (right, solid) growth curves as they reach N_T . In these plots, we can then determine the change in survival (vertical black lines). The change in this time represents the Δt_f and Δt_s for each intervention in the fast and slow curves, respectively. Notably, the x-axis for the faster (left, dotted) growth curves accounts for fewer days, despite having the same relative length as the x-axis for the slower (right, solid) growth curves. This was necessary in order to annotate the smaller Δt_f for the faster growth curves.

Supplementary Fig 2. A visual representation across seven ODE tumor growth models, demonstrating that earlier intervention creates a larger improvement in OS. Models were produced using the parameters denoted by Murphy et al (33), where the seven models were fit to 14 timepoints of xenograft tumor growth data from Worschech et al (40). **A.** A comparison of the seven growth curves with no interventions built with various ODE models. **B-H.** Individual plots visually demonstrating the change in OS for three intervention times for all models included in A. The calculation of change in OS, is demonstrated in Figure 1 with the calculation of Δt .